New CAR-T therapy challenges standard in major lymphoma trial
NCT ID NCT07479797
Summary
This study aims to see if a new cell therapy called KITE-753 works better than the current standard therapy (axi-cel) for adults with aggressive large B-cell lymphoma that has come back or didn't respond to their first treatment. About 550 participants will be randomly assigned to receive one of the two CAR T-cell therapies. The main goal is to see which treatment leads to more people being cancer-free at 6 months and living longer without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.